RxDoctor Payments Data

Katherine McDuffie

Nurse Practitioner · Tupelo, MSNPI 1114252160

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 77 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$269
  • Angiodynamics, Inc.$224
  • Alnylam Pharmaceuticals Inc.$210
  • Amgen$190
  • Boston Scientific$117
  • Merck$105
  • plus $226 from 5 others

What the payments were for

  • Travel & lodging$544%
  • Food & beverage$1,28896%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,342 in reported general payments places this provider in the 75th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$253,841
Medicare patients
1,459
Services billed
5,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban345$282,784
EntrestoSacubitril/Valsartan187$194,832
XareltoRivaroxaban178$167,818
Repatha SureclickEvolocumab145$123,128
FarxigaDapagliflozin Propanediol83$91,690
BrilintaTicagrelor65$48,186
JardianceEmpagliflozin24$23,019
Praluent PenAlirocumab16$18,657
Ranolazine ErRanolazine172$15,498
Metoprolol Succinate1,296$13,871
Rosuvastatin Calcium956$9,946
Ezetimibe469$8,031
Isosorbide Mononitrate ErIsosorbide Mononitrate629$5,421
Isosorbide Dinitrate105$5,267
Carvedilol934$4,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$269$282,784345 claims
NovartisEntresto$99$194,832187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →